India-based Zenara Pharma Private Limited, a Biophore company, announced on Thursday that it has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Capsules, 150 mg and 200 mg.
This approval marks the first FDA-approved generic equivalent of the reference listed drug marketed by Almatica Pharma LLC.
The product has also been granted Competitive Generic Therapy (CGT) designation by the FDA. As the first approved applicant under this pathway, Zenara's ANDA has secured 180 days of marketing exclusivity in the United States, which commenced with the product's launch.
Sertraline Hydrochloride Capsules are classified as selective serotonin reuptake inhibitors (SSRIs) and are indicated for the treatment of Major Depressive Disorder (MDD) in adults and obsessive-compulsive disorder (OCD) in adults and paediatric patients aged six years and older.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval